Novo Nordisk Pharma, a global company driving change to defeat diabetes and other serious chronic conditions such as haemophilia and growth disorders, has signed an extension of the current contract with DKSH Taiwan. Under the new agreement, DKSH will become an exclusive distributor for Novo Nordisk Pharma's complete health care products in Taiwan.
Media release
Taipei, Taiwan, December 27, 2019 – DKSH Business Unit Healthcare, the leading partner for healthcare companies seeking to grow their business in Asia, has been a distributor for Novo Nordisk's haemophilia products in Taiwan since 2005. DKSH will take over the distribution and logistics services for Novo Nordisk Pharma from January 1, 2020.
Novo Nordisk Pharma chose DKSH due to its capillary distribution network, excellent proven track record in the healthcare sector as well as strong logistics capabilities. DKSH is the leading healthcare distributor in Taiwan, being the first accredited by Taiwan Food and Drug Administration's Pharmaceutical Inspection Co-operation Scheme for Good Distribution Practices (PICs/GDP) requirements.
Wennie Chang, Vice President, Business Unit Healthcare, DKSH Taiwan, commented: “We are very pleased that our collaboration with Novo Nordisk Pharma has flourished into a deeper partnership. We look forward to providing our high-quality cold chain services for Novo Nordisk Pharma's temperature-sensitive products. We will also offer high-standard facilities and service flexibility to accommodate any future products that Novo Nordisk Pharma is planning to introduce to the Taiwan market.”
Steve Profit, General Manager of Novo Nordisk Pharma (Taiwan) Ltd., added: “For Novo Nordisk, it is critical that we have a distribution partner that shares our business ethics and drive to offer the best services to our customers. That is why we are delighted to have DKSH as our exclusive distributor. With DKSH's professional logistics services, including emergency and time-specified delivery, I am confident that together we will be able to provide the best quality products and local distribution services to fulfill the needs of our customers and end-users of our products.”
In addition to distribution and logistics, DKSH Taiwan Business Unit Healthcare offers a wide-range of services, including and not limited to market research, regulatory affairs, product registry, tender business and patient solution programs to the local healthcare industry.
For further information, please contact
Novo Nordisk
Loren Tsai
Patient Support and Public Relations Director
Phone+886 2 23772566 #101
swts@novonordisk.com
DKSH Taiwan
Stacy Lee
Manager, Branding & Communications
Phone +886 2 8752 7290
stacy.lee@dksh.com
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,200 people in 80 countries, and markets its products in more than 170 countries. In 1990, Novo Nordisk Pharma (Taiwan) Ltd. was incorporated in Taipei and it has been a leader in improving the lives of patients with diabetes and haemophilia. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
About DKSH
DKSH is the leading Market Expansion Services provider with a focus on Asia. The Group helps other companies and brands to grow in the Consumer Goods, Healthcare, Performance Materials and Technology sectors. DKSH’s portfolio of services includes sourcing, market insights, marketing and sales, distribution and logistics as well as after-sales services. Publicly listed on the SIX Swiss Exchange, the Group operates in 35 markets with 33,000 specialists, generating net sales of CHF 11.3 billion in 2018. With its strong Swiss heritage and long business tradition since 1865, DKSH is deeply rooted in Asia Pacific. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and overt-the-counter (OTC) products as well as medical devices. With around 8,800 specialists, the Business Unit generated net sales of CHF 6.1 billion in 2018.